Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits

Recent developments in targets for ischemic foot disease

“…[48][49][50][51][52][53][54][55][56][57] The VOYAGER sub study reported the efficacy of the anti-coagulant drug rivaroxaban at low dose in patients with PAD undergoing open surgical revascularisation, finding that the composite outcome of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke and cardiovascular death were significantly reduced by allocation to rivaroxaban. 58 Findings were similar in the COMPASS trial. 60 Another trial tested a programme designed to improve patient self-management after major amputation for CLTI and found no effect of the intervention on musculoskeletal function but a significant improvement in the psycho-social and quality of life outcome measure.…”

“…Twelve randomised controlled trials were identified published since 2017 that tested a range of medical and rehabilitation therapies in patients with CLTI (Table 2). [48][49][50][51][52][53][54][55][56][57][58][59] Women were under-represented, being between 0% and 38% of the enroled patients (Table 2), thus highlighting the unmet need of gender equality in this field. The interventions tested mainly aimed to promote angiogenesis or arteriogenesis using growth factors or stem cells, including plasmids designed to upregulate Hepatocyte growth factor (HGF) or SDF-1, umbilical cord blood platelet gel, bone marrow aspirates, mononuclear cells, mesenchymal stem cells and endothelial cell progenitors.…”